UB Paderborn / Katalog / Suche / in CDI

Es ist ein Fehler in der Kommunikation mit einem externen System aufgetreten. Bitte versuchen Sie Ihre letzte Aktion erneut. Sollte der Fehler bestehen bleiben, setzen Sie sich bitte mit dem Informationszentrum der Bibliothek in Verbindung oder versuchen Sie es später erneut.

1 – 25 von 228

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

Kidney international, 2014-04, Vol.85 (4), p.962-971

2014

Volltextzugriff (PDF)

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

Diabetes care, 2012-07, Vol.35 (7), p.1473-1478

2012

Volltextzugriff (PDF)

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

Diabetes care, 2010-10, Vol.33 (10), p.2217-2224

2010

Volltextzugriff (PDF)

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

BMC medicine, 2013-02, Vol.11 (1), p.43-43, Article 43

2013

Volltextzugriff (PDF)

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2010-06, Vol.375 (9733), p.2223-2233

2010

Volltextzugriff (PDF)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

Diabetes care, 2009-04, Vol.32 (4), p.650-657

2009

Volltextzugriff (PDF)

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

Kidney international, 2011-03, Vol.79 (S120), p.S20-S27

2011

Volltextzugriff (PDF)

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

Metabolism, clinical and experimental, 2018-08, Vol.85, p.32-37

2018

Volltextzugriff (PDF)

Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria

Diabetes research and clinical practice, 2014-03, Vol.103 (3), p.373-381

2014

Volltextzugriff (PDF)

Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study

Clinical therapeutics, 2014, Vol.36 (1), p.84-100.e9

2014

Volltextzugriff (PDF)

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study

Diabetes care, 2015-03, Vol.38 (3), p.412-419

2015

Volltextzugriff (PDF)

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

Journal of diabetes and its complications, 2013-09, Vol.27 (5), p.479-484

2013

Volltextzugriff (PDF)

Urinary tract infections in patients with diabetes treated with dapagliflozin

Journal of diabetes and its complications, 2013-09, Vol.27 (5), p.473-478

2013

Volltextzugriff (PDF)

Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events

Drug safety, 2014-10, Vol.37 (10), p.815-829

2014

Volltextzugriff (PDF)

Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment

Diabetes care, 2009-09, Vol.32 (9), p.1656-1662

2009

Volltextzugriff (PDF)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era

Diabetes, obesity & metabolism, 2018-10, Vol.20 (S3), p.14-18

2018

Volltextzugriff (PDF)

Effects of Dapagliflozin on Cardiovascular Risk Factors

Postgraduate medicine, 2013-05, Vol.125 (3), p.181-189

2013

Volltextzugriff (PDF)

Cure of Overt Diabetes in NOD Mice by Transient Treatment With Anti-Lymphocyte Serum and Exendin-4

Diabetes (New York, N.Y.), 2004-07, Vol.53 (7), p.1700-1705

2004

Volltextzugriff (PDF)

Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells

American journal of physiology: endocrinology and metabolism, 2004-06, Vol.286 (6), p.E875-E881

2004

Volltextzugriff (PDF)

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

BMC medicine, 2013-09, Vol.11, p.193-193

2013

Volltextzugriff (PDF)

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

Diabetes care, 2012-07, Vol.35 (7), p.1473-1478

2012

Volltextzugriff (PDF)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

Diabetes, metabolic syndrome and obesity, 2012-01, Vol.5 (default), p.135-148

2012

Volltextzugriff (PDF)

Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin

Regulatory peptides, 2006-05, Vol.134 (2), p.149-157

2006

Volltextzugriff (PDF)

Defective Melanocortin 4 Receptors in Hyperphagia and Morbid Obesity

The New England journal of medicine, 2003-03, Vol.348 (12), p.1160-1163

2003

Volltextzugriff (PDF)

Synergy Between Scientific Advancement and Technological Innovation, Illustrated by a Mechanism-Based Model Characterizing Sodium-Glucose Cotransporter-2 Inhibition

Journal of clinical pharmacology, 2010-09, Vol.50 (S9), p.113S-120S

2010

Volltextzugriff (PDF)

1 – 25 von 228

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(176)
Mit Volltextzugriff
(179)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(112)
Life Sciences & Biomedicine
(92)
Humans
(67)
Male
(46)
Female
(41)
Middle Aged
(33)
Aged
(26)
Adult
(25)
Biological And Medical Sciences
(24)
Animals
(23)
Social Sciences
(23)
Diabetes
(22)
Diabetes Mellitus, Type 2 - Drug Therapy
(22)
Endocrinology & Metabolism
(19)
Medical Sciences
(18)
Business & Economics
(16)
Economics
(15)
Hypoglycemic Agents - Therapeutic Use
(14)
Treatment Outcome
(14)
Benzhydryl Compounds
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria

Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

Urinary tract infections in patients with diabetes treated with dapagliflozin

Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events

Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era

Effects of Dapagliflozin on Cardiovascular Risk Factors

Cure of Overt Diabetes in NOD Mice by Transient Treatment With Anti-Lymphocyte Serum and Exendin-4

Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin

Defective Melanocortin 4 Receptors in Hyperphagia and Morbid Obesity

Synergy Between Scientific Advancement and Technological Innovation, Illustrated by a Mechanism-Based Model Characterizing Sodium-Glucose Cotransporter-2 Inhibition

Suchergebnisse filtern